Bromodomain and Extra-Terminal Family Proteins BRD2, BRD3, and BRD4 Contribute to H19-Dependent Transcriptional Regulation of Cell Adhesion Molecules, Modulating Metastatic Dissemination Program in Prostate Cancer

Valeria Pecci, M Borsa, Aurora Aiello, Sara De Martino, Luca Cis, Cristian Ripoli, Dante Rotili, Francesco Pierconti, Francesco Pinto, Claudio Grassi, Carlo Gaetano, Antonella Farsetti, Simona NanniNon-Coding 2025 · DOI

TL;DR

This study reveals that the BET proteins, particularly BRD4, play a crucial role in prostate cancer metastasis by epigenetically regulating the long non-coding RNA H19 and its control over cell adhesion molecules. This H19/BRD4 axis is a promising therapeutic target for advanced prostate cancer, as its function is independent of androgen receptor status.

What Problem Does This Paper Address?

Prostate cancer (PCa) remains a significant health challenge, with a substantial portion of cases progressing to metastatic disease, which is notoriously difficult to treat. While androgen receptor (AR) signaling has been a primary focus for therapy, understanding the mechanisms driving metastasis beyond AR is critical for developing new strategies. Collective cell migration, a key feature of metastatic dissemination, involves intricate regulation of cell adhesion molecules. This paper investigates how the Bromodomain and Extra-Terminal (BET) family proteins, known epigenetic readers, contribute to this process, specifically focusing on their interaction with the long non-coding RNA H19 and its role in regulating cell adhesion molecules in both AR-positive and AR-null prostate cancer contexts.

Methods

The researchers employed a multi-pronged approach to dissect the H19/BET protein axis in prostate cancer metastasis:

  • Cell Culture and Treatment: They utilized established prostate cancer cell lines (PC-3, 22Rv1, and Du145), including AR-null and AR-positive variants. These cells were treated with various BET inhibitors (JQ1, OTX015, dBET6) and selective inhibitors (Bi7273 for BRD9, LT052 for BRD4 BD1) to assess their impact on gene expression and cell proliferation. Stable H19 silencing (siH19) was also performed to investigate H19's role.
  • Molecular and Cellular Assays:
    • qPCR: Used to quantify mRNA levels of cell adhesion molecules like E-cadherin (CDH1) and β4 integrin (ITGB4).
  • Western Blotting: Employed to assess protein levels of E-cadherin and β4 integrin.
  • IncuCyte Live Cell Imaging: Utilized to monitor and quantify cell proliferation.
  • Epigenetic and Chromatin Analysis:
    • Chromatin Immunoprecipitation (ChIP): Performed to determine the binding of BET proteins (BRD2, BRD3, BRD4) and histone modifications (H3K27ac, H4K12ac) to the regulatory regions of CDH1 and ITGB4.
  • RNA-Chromatin Immunoprecipitation (RNA-ChIP): Used to investigate direct interactions between H19 and BET proteins on chromatin.
  • In Vivo and Ex Vivo Models:
    • Subcutaneous Murine Xenograft Model: H19-silenced and control PC-3 cells were implanted in NOD/SCID mice, and the effects of JQ1 treatment on tumor growth and adhesion molecule expression were evaluated.
  • Organotypic Slice Cultures (OSCs): Patient-derived prostate cancer tissue explants were used as an ex vivo model to assess the impact of BET inhibitors on adhesion molecule expression and BRD4 recruitment in a more physiologically relevant setting.

Datasets

The study primarily utilized established human prostate cancer cell lines (PC-3, 22Rv1, Du145) and patient-derived organotypic slice cultures (OSCs) from a cohort of 22 PCa patients. Publicly available data from the ENCODE database was used to identify H3K27ac enrichment in the regulatory regions of CDH1 and ITGB4. No new benchmark datasets were introduced.

Key Insights and Ideas

  • H19 as a Regulator of BET Protein Recruitment: The study reveals that H19 acts as a negative modulator of BRD4's genomic occupancy. When H19 is silenced, BRD4 recruitment to the promoters of cell adhesion genes (CDH1 and ITGB4) is significantly enhanced. This suggests H19 normally acts as a scaffold or decoy, limiting BRD4's access to these critical gene loci.
  • BRD4's Role in Collective Migration: Contrary to BRD4's known role in promoting EMT, this study highlights its function in maintaining E-cadherin expression and promoting a cohesive, collective migration phenotype in prostate cancer. This is a context-specific role that emphasizes the nuanced functions of epigenetic regulators.
  • AR-Independent Mechanism: A crucial finding is that the H19/BRD4 axis's influence on cell adhesion molecules and metastatic dissemination is independent of androgen receptor (AR) status. This broadens the therapeutic potential of targeting this pathway to a wider range of prostate cancer subtypes, including castration-resistant and AR-null forms.
  • Clinical Relevance in Patient Tissues: The validation of these findings in organotypic slice cultures derived from human prostate cancer tissues, particularly those from patients who experienced recurrence, underscores the translational significance of the H19/BRD4 axis.

Key Results

  • BET inhibition (using JQ1, OTX015, dBET6) significantly reduced E-cadherin and β4 integrin expression and cell proliferation in both AR-null (PC-3) and AR-positive (22Rv1) prostate cancer cells, even after H19 knockdown.
  • In vivo studies in xenograft models showed that JQ1 treatment led to tumor growth inhibition and downregulation of adhesion molecule markers.
  • ChIP assays demonstrated that BRD4, more so than BRD2/3, is enriched at the promoters of CDH1 and ITGB4, particularly in H3K27ac-marked regions.
  • RNA-ChIP confirmed a specific interaction between BRD4 and H19, suggesting a direct molecular link.
  • Organotypic slice cultures from prostate cancer patients showed reduced CDH1 and ITGB4 expression upon JQ1 or dBET6 treatment, with a trend towards greater sensitivity in samples from patients with recurrence.

Limitations and Future Work

The authors acknowledge several limitations:

  • Precise Molecular Mechanism: The exact molecular details of how H19 interferes with BRD4 chromatin binding are not fully elucidated.
  • Inter-Sample Variability: While OSCs provide a valuable patient-derived model, variability between samples might affect the generalizability of findings.
  • Off-Target Effects of BET Inhibitors: BET inhibitors have broad epigenetic activity, and off-target effects cannot be entirely excluded.
  • In Vivo Metastasis Studies: While xenograft models showed tumor growth inhibition, in vivo studies specifically evaluating the metastatic potential under BETi treatment are warranted for a more comprehensive assessment of therapeutic efficacy.

Future work could focus on dissecting the precise molecular interactions between H19 and BRD4, exploring domain-selective BET inhibitors for enhanced specificity, and conducting further in vivo studies to fully assess the therapeutic potential of targeting the H19/BRD4 axis in metastatic prostate cancer.

Summary updated

Abstract

Our study demonstrates that BRD4 epigenetically regulates the <i>H19</i>-mediated transcriptional control of adhesion molecules involved in collective migration and metastatic dissemination. Importantly, these effects are independent of AR status, suggesting that targeting the <i>H19</i>/BRD4 axis may represent a promising therapeutic avenue for advanced PCa.
BibTeX
@inproceedings{pecci2025bromodomain,
  author = {Valeria Pecci and M Borsa and Aurora Aiello and Sara De Martino and Luca Cis and Cristian Ripoli and Dante Rotili and Francesco Pierconti and Francesco Pinto and Claudio Grassi and Carlo Gaetano and Antonella Farsetti and Simona Nanni},
  title = {{Bromodomain and Extra-Terminal Family Proteins BRD2, BRD3, and BRD4 Contribute to H19-Dependent Transcriptional Regulation of Cell Adhesion Molecules, Modulating Metastatic Dissemination Program in Prostate Cancer}},
  booktitle = {Non-Coding},
  year = {2025},
  doi = {10.3390/ncrna11030033},
}
Figure